Advertisement

Etelcalcetide: a new intravenous calcimimetic for the treatment of secondary hyperparathyroidism in haemodialysis patients

Etelcalcetide: a new intravenous calcimimetic for the treatment of secondary hyperparathyroidism in haemodialysis patients

Etelcalcetide: un nuovo calciomimetico per la terapia dell’iperparatiroidismo secondario nei pazienti in emodialisi

G Tec Nefrol Dial 2017; 29(1): 62 - 65

Article Type: SPECIAL FOCUS REVIEW

Article Subject: TN&D JOURNAL CLUB

DOI:10.5301/GTND.2017.16649

Authors

Monica Limardo, Giuseppe Pontoriero

Abstract

Etelcalcetide hydrochloride (also known as AMG 416) is a new, second generation, long-acting calcimimetic agent that is administered intravenously. In November 2016 it received its first approval in the UE for the treatment of secondary hyperparathyroidism (SHPT) in adult haemodialysis patients. This article summarizes the results of pre-clinical and clinical studies which demonstrated that Etelcalcetide decreases effectively PTH levels. Although questions about this new compound remain open, and further studies are required to assess clinical hard outcomes as well as long term efficacy and safety, Etelcalcetide represents a new therapeutic option for the challenging treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).

Article History

This article is available as full text PDF.

Download any of the following attachments:

Authors

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.